Pembrolizumab plus chemotherapy for advanced gastric cancer - Authors' reply

Lancet Oncol. 2024 Feb;25(2):e52. doi: 10.1016/S1470-2045(24)00022-6.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Humans
  • Lung Neoplasms* / drug therapy
  • Stomach Neoplasms* / drug therapy

Substances

  • pembrolizumab
  • Antibodies, Monoclonal, Humanized